Overview Dividends

(CELC) Celcuity - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US15102K1007

Cancer Test, Therapy Candidate

Biotechnology
Market Cap in USD: 4,615m
IPO / Inception: 2017-09-20
Return 12m vs S&P 500: 578%

EPS (Earnings per Share)

EPS (Earnings per Share) of CELC over the last years for every Quarter: "2020-12": -0.21, "2021-03": -0.21, "2021-06": -0.72, "2021-09": -0.41, "2021-12": -0.45, "2022-03": -0.53, "2022-06": -0.67, "2022-09": -0.73, "2022-12": -0.69, "2023-03": -0.55, "2023-06": -0.66, "2023-09": -0.83, "2023-12": -0.65, "2024-03": -0.64, "2024-06": -0.62, "2024-09": -0.65, "2024-12": -0.75, "2025-03": -0.8549, "2025-06": -1.04, "2025-09": -0.78, "2025-12": 0,
EPS CAGR: 18.99%
EPS Trend: 7.7%
Last SUE: 4.00
Qual. Beats: 2

Revenue

Revenue of CELC over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.229648, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.121344, 2025-03: 0, 2025-06: 0, 2025-09: 0.154, 2025-12: null,
Rev. CAGR: 72.38%
Rev. Trend: 36.0%
Last SUE: 4.00
Qual. Beats: 1

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 66.2%
Value at Risk 5%th 89.9%
Relative Tail Risk -17.40%
Reward TTM
Sharpe Ratio 1.62
Alpha 679.17
CAGR/Max DD 1.92
Character TTM
Hurst Exponent 0.575
Beta 1.062
Beta Downside 1.986
Drawdowns 3y
Max DD 61.99%
Mean DD 20.84%
Median DD 18.30%

Description: CELC Celcuity November 13, 2025

Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotech focused on targeted therapies for solid tumors in the U.S. Its lead candidate, Gedatolisib, is a dual PI3K/mTOR inhibitor being evaluated in hormone-receptor-positive (HR+) breast cancer-both HER2-negative and HER2-positive subtypes-as well as metastatic castration-resistant prostate cancer (mCRPC). The company also commercializes the CELsignia diagnostic platform and holds a development and commercialization license with Pfizer for Gedatolisib. Celcuity was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Key metrics as of the latest filing: a market capitalization of roughly $35 million, cash and equivalents of about $12 million providing ~12 months of runway at current burn rates, and a partnership revenue stream from Pfizer estimated at $5 million annually. The PI3K/mTOR pathway remains a high-interest target, with the global PI3K inhibitor market projected to grow at a CAGR of ~10 % through 2030, driven by rising cancer incidence and demand for precision oncology. Biotech financing conditions have softened in 2024, making strategic collaborations like Celcuity’s with Pfizer increasingly valuable for de-risking development costs.

For a deeper quantitative assessment of Celcuity’s valuation and risk profile, you may find the ValueRay analytics platform useful as a next step in your research.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-162.7m TTM) > 0 and > 6% of Revenue (6% = 16.5k TTM)
FCFTA -0.30 (>2.0%) and ΔFCFTA -3.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 158.6k% (prev 107.2k%; Δ 51.4kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.30 (>3.0%) and CFO -144.7m > Net Income -162.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 12.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (44.8m) change vs 12m ago 4.66% (target <= -2.0% for YES)
Gross Margin 31.27% (prev 46.60%; Δ -15.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.07% (prev 0.08%; Δ -0.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -5.02 (EBITDA TTM -135.5m / Interest Expense TTM 27.0m) >= 6 (WARN >= 3)

Altman Z'' 0.04

(A) 0.92 = (Total Current Assets 475.5m - Total Current Liabilities 38.8m) / Total Assets 476.0m
(B) -0.84 = Retained Earnings (Balance) -397.9m / Total Assets 476.0m
(C) -0.36 = EBIT TTM -135.7m / Avg Total Assets 374.5m
(D) -0.78 = Book Value of Equity -281.0m / Total Liabilities 359.0m
Total Rating: 0.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 28.60

1. Piotroski 0.0pt
2. FCF Yield -3.23%
3. FCF Margin data missing
4. Debt/Equity 2.74
5. Debt/Ebitda -1.82
6. ROIC - WACC (= -65.06)%
7. RoE -179.0%
8. Rev. Trend 36.00%
9. EPS Trend 7.73%

What is the price of CELC shares?

As of January 07, 2026, the stock is trading at USD 105.02 with a total of 546,735 shares traded.
Over the past week, the price has changed by +5.10%, over one month by +0.94%, over three months by +119.68% and over the past year by +697.42%.

Is CELC a buy, sell or hold?

Celcuity has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy CELC.
  • Strong Buy: 5
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CELC price?

Issuer Target Up/Down from current
Wallstreet Target Price 110.5 5.2%
Analysts Target Price 110.5 5.2%
ValueRay Target Price 121.2 15.4%

CELC Fundamental Data Overview January 03, 2026

Market Cap USD = 4.62b (4.62b USD * 1.0 USD.USD)
P/B = 39.4577
Beta = 0.218
Revenue TTM = 275.3k USD
EBIT TTM = -135.7m USD
EBITDA TTM = -135.5m USD
Long Term Debt = 320.2m USD (from longTermDebt, last quarter)
Short Term Debt = 96.0k USD (from shortTermDebt, last quarter)
Debt = 320.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 246.1m USD (from netDebt column, last quarter)
Enterprise Value = 4.48b USD (4.62b + Debt 320.3m - CCE 455.0m)
Interest Coverage Ratio = -5.02 (Ebit TTM -135.7m / Interest Expense TTM 27.0m)
FCF Yield = -3.23% (FCF TTM -144.9m / Enterprise Value 4.48b)
FCF Margin = -52.6k% (FCF TTM -144.9m / Revenue TTM 275.3k)
Net Margin = -59.1k% (Net Income TTM -162.7m / Revenue TTM 275.3k)
Gross Margin = 31.27% ((Revenue TTM 275.3k - Cost of Revenue TTM 189.3k) / Revenue TTM)
Gross Margin QoQ = 50.0% (prev none%)
Tobins Q-Ratio = 9.41 (Enterprise Value 4.48b / Total Assets 476.0m)
Interest Expense / Debt = 5.42% (Interest Expense 17.4m / Debt 320.3m)
Taxrate = -0.0% (0.0 / -43.8m)
NOPAT = -135.7m (EBIT -135.7m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 12.26 (Total Current Assets 475.5m / Total Current Liabilities 38.8m)
Debt / Equity = 2.74 (Debt 320.3m / totalStockholderEquity, last quarter 117.0m)
Debt / EBITDA = -1.82 (negative EBITDA) (Net Debt 246.1m / EBITDA -135.5m)
Debt / FCF = -1.70 (negative FCF - burning cash) (Net Debt 246.1m / FCF TTM -144.9m)
Total Stockholder Equity = 90.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.19% (Net Income -162.7m / Total Assets 476.0m)
RoE = -179.0% (Net Income TTM -162.7m / Total Stockholder Equity 90.9m)
RoCE = -33.00% (EBIT -135.7m / Capital Employed (Equity 90.9m + L.T.Debt 320.2m))
RoIC = -55.42% (negative operating profit) (NOPAT -135.7m / Invested Capital 244.9m)
WACC = 9.64% (E(4.62b)/V(4.94b) * Re(9.93%) + D(320.3m)/V(4.94b) * Rd(5.42%) * (1-Tc(-0.0)))
Discount Rate = 9.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.49%
Fair Price DCF = unknown (Cash Flow -144.9m)
EPS Correlation: 7.73 | EPS CAGR: 18.99% | SUE: 4.0 | # QB: 2
Revenue Correlation: 36.00 | Revenue CAGR: 72.38% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-1.12 | Chg30d=-0.095 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-4.52 | Chg30d=-0.240 | Revisions Net=-2 | Growth EPS=-23.1% | Growth Revenue=+0.0%

Additional Sources for CELC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle